Page 1,183«..1020..1,1821,1831,1841,185..1,1901,200..»

‘Big dreams and aspirations’: Mourning family, friends remember Carleton student Fareed Arasteh killed in Tehran – The Charlatan

Posted: January 16, 2020 at 1:44 pm

On a cloudy Sunday in Tehran, Fareed Arasteh married the love of his life, hoping she would join him in Ottawa before he finished his doctorate program at Carleton.

Anxious, as he packed his bags before his flight back to Iran, Arasteh asked his fiance Maral Gorginpours cousin Golnaz Shaverdi for help. Shaverdi, an engineer who lives a couple hours away in Montreal, was a welcome distraction for Arasteha bundle of nerves before his big day, she said. Together, they found the perfect suit for his perfect wedding.

Arasteh would never return back to Ottawa.

Three days after his wedding, the biology student was among 176 passengers and crew members57 of them Canadian citizens and 138 headed to Canadaon board Ukrainian flight PS752 en route to Kyiv on Jan. 8.

All 176 of them were killed shortly after take-off from Tehran. At the age of 32, Arasteh was one of them.

But hes not here anymore. Now Im just trying to put myself back together again.

Samanfar and Arasteh became fast pals after mutual friends introduced the two in Tehran. A few years later, they reconnected when Arasteh joined Carleton in August last fall.

It was like the ideal situation, said Samanfar, who also studied at Carleton. We were fulfilling our dreams by working hard, and living with a friend comfortably.

Arasteh excitedly spoke with Samanfar after his wedding, sending him pictures, and letting him know hed be home on Wednesday.

On Tuesday night, Samanfar was about to go to bed when he texted Arasteh to let him know he arrived in Kyiv. He thought hed pick his friend up from the airport the next day.

His friend never texted back.

Those hours were the hardest, said Samanfar. When I saw the news, my heart sank. I didnt want to believe it, even though I knew at the back of my mind that Fareed was on that plane.

I kept refreshing pages. Finally, his name showed up.

Arastehs friends and family remember him as a soft-spoken, genuinely kind, and thoughtful person with a generous soul. He maintained long, beautiful friendships, taking good care of everyone around him and always checking up on them, they said.

In interviews with the Charlatan, several of those closest to Arasteh broke down in tears recalling memories they shared.

I dont know what Im supposed to do anymore. I dont know what to say to anyone, said Arastehs wife Gorginpour, mewling in a brief conversation over the phone. We had such big dreams and aspirations. Its hard to even talk about any of it without crying like this.

I just want people to know how great my Fareed is.

Salman Soltanian cant quite put a finger to what country song Arasteh and him listened to most back in Tehran. There were so, so many of them, he said, cracking a small smile through his tears.

He loved photography and Shania Twain, said Azad Heidari, Arastehs friend from the University of Tehran.

Kiarash Pedram and Jaber Rahimi were right next to Arasteh when he found out he was accepted into the competitive molecular genetics doctorate program at Carleton. It was so exciting and so happy to watch him, said Pedram.

Biology professor Ashkan Golshani, who was supervising Arastehs PhD, said he expected big things from his star student who always asked deep questions.

Arasteh joined Carletons molecular genetics lab after finishing a masters degree in biotechnology from Iran. His researchidentifying and characterizing genes that affect quality control of the gene expressionwas a large part of a $200,000-funded project, working towards a cure for cancer.

He didnt just do fantastic work himself, he helped others around him, helping them work hard as well, said Golshani.

Arasteh hoped to graduate in 2023.

A vigil in his honour will be held in the Tory foyer Wednesday, Jan. 15 from 2 to 3 p.m. Condolence books will be available for members of the community to sign.

Iran had denied its involvement in the crash for several days before admitting it unintentionally shot down the Ukrainian airliner on Jan. 11 by human error, following weeks of tensions with the U.S.

Prime Minister Justin Trudeau has called for financial compensation for the victims families and a thorough investigation. We need to make sure those in mourning get the justice they deserve, he said at the University of Alberta, one of multiple vigils held across Canada since the crash.

Featured image provided by Fareed Arastehs family.

See the article here:
'Big dreams and aspirations': Mourning family, friends remember Carleton student Fareed Arasteh killed in Tehran - The Charlatan

Posted in Molecular Genetics | Comments Off on ‘Big dreams and aspirations’: Mourning family, friends remember Carleton student Fareed Arasteh killed in Tehran – The Charlatan

Tyson Fury claims he is masturbating SEVEN TIMES A DAY to keep testosterone pumping ahead of huge Deontay – The Sun

Posted: January 16, 2020 at 1:43 pm

TYSON FURY has revealed he is masturbating SEVEN times a day ahead of his big rematch against Deontay Wilder.

And the Gypsy King hopes it will give him the 'upper hand' as he bids to become WBC world heavyweight champ.

5

The two boxers will go 'at it' for Part II in Las Vegas after their controversial draw in December 2018.

And in a bid to keep his "testosterone flowing" Fury has admitted to one special way to release energy.

Speaking after the first press conference concluded ahead of the big fight, the 31-year-old said: "I'm doing a lot of things I didn't before.

"I'm eating five/six meals a day, drinking eight litres of water. If it's gonna give me an edge, I'm willing to try it.

"I'm masturbating seven times a day to keep my testosterone pumping."

Fury, married to wife Paris since 2008 with the couple having five children, then quoted lines from the 2004 hit song by Danzel, titled Pump It Up.

He added: "Pump it, pump it, pump it, pump it up! Dontcha know!

"I gotta to keep active and the testosterone flowing for the fight. Don't want the levels to go down."

It's not the first time sport stars might have resorted to solo tactics to improve 'performance'.

SunSport reported how sexologist and wife of Wolves keeper Rui Patricio advised the Portugal squad to masturbate at the World Cup.

And Albanian model Erjona Sulejmani, wife of Serie A star Blerim Dzemaili, has claimed many footballers turn down sex before games - and instead do it themselves.

5

5

DOES SEX BEFORE SPORT BOOST PERFORMANCE?

THERE has been numerous studies into how sex could affect athletic performance.

And unfortunately the waters are pretty murky as far as this is concerned.

An expert writing for The Conversation on the topic concludes that "there is no detrimental or beneficial effect of sexual activity before competition on subsequent athletic performance".

However, 'chasing sex' could indeed be detrimental, as it could come with 'sleep deprivation and alcohol/drug consumption' that could affect athletic performance.

Curfews are often placed on athletes to ensure the mind and body is well rested before competition.

One study reports that the effects of sex on athletic performance only come to light when the element of 'time' is considered.

Laura Stefani, an assistant professor of sports medicine at the University of Florence, Italy, said: 'We show no robust scientific evidence to indicate that sexual activity has a negative effect upon athletic results.

'In fact, unless it takes place less than two hours before, the evidence actually suggests sexual activity may have a beneficial effect on sports performance.'

Fury will be hoping to 'shake' things up come February 22 and hand Wilder his first ever defeat as a pro boxer.

SunSport reported howFury claims he will have one of the easiest nights of his career by knocking Wilder out in ROUND TWO of their rematch.

The 31-year-old Gypsy King is famous for his fabulous footwork and point scoring shots and claims he will be slippery like a goldfish on fight night.

Before his round-two win against tune-up opponent Tom Schwarz last June, the 6ft 9in ace had not won inside the opening six minutes since a 2010 walkover at Huddersfield Sports Centre.

But the superstitious former unified champ has been getting signs that the second stanza will be the deciding one on February 22.

Fury said: I am going to win the fight,Deontaycan make up all the excuses he wants, he lost the first fair and square and the same will happen in the second.

I have never been of sure of anything in my whole life, I am going to kick that mother f*****s arse all over the ring.

I have not had to lose any weight.

Pictured

'LEAN' Fury spars ten rounds with four boxers and shows off dad bod ahead of Wilder fight

NO TRAIN NO GAIN AJ shows off explosive power in training ahead of Pulev bout after holiday

LOAD OF ISTANBUL? Joshua vs Pulev fight to take place in Istanbul in May, claims challenger

'PACKING TIMBER' Fury piles on pounds to KO Wilder after grim injury vs Wallin at just 18st

PRICE IS RIGHT BT KO Sky to land UK TV rights for Fury vs Wilder 2 despite '10m bid'

'YOU LITTLE BITCH' Watch Fury taunt Wilder over nose piercing in behind-the-scenes footage

5

He has had to get out of jail a few times with his right hand but it will not be there this time, I will be super slippery, like a goldfish in a bowl.

Fury is well known for creating a stir before his fights, and he chose the first press conference to slam Wilder's nose piercing.

After the American said he will "baptise" Fury, the Brit called Wilder a "little b****" for having the facial jewellery.

5

Originally posted here:
Tyson Fury claims he is masturbating SEVEN TIMES A DAY to keep testosterone pumping ahead of huge Deontay - The Sun

Posted in Testosterone Shots | Comments Off on Tyson Fury claims he is masturbating SEVEN TIMES A DAY to keep testosterone pumping ahead of huge Deontay – The Sun

Horizon Discovery to Provide Access to Novel Base Editing Technology – Yahoo Finance

Posted: January 15, 2020 at 2:42 am

Horizon Discovery Group plc (LSE: HZD) ("Horizon", "the Company" or "the Group"), a global leader in the application of gene editing and gene modulation technologies, today announced that it will provide access to a novel base editing technology licensed from Rutgers, The State University of New Jersey, for exclusive use in therapeutic, diagnostic and services applications. This technology is incorporated into Horizons next-generation gene editing platform to enable the development of novel therapeutics that rely on engineering patients cells either directly in the body (gene therapy), or externally before transplanting back into the patient (cell therapy). This platform will also expand the Companys research tools and service provisions.

The Company formed an exclusive partnership with Rutgers in January 2019 to further develop the novel base editing technology invented by Dr. Shengkan Jin, associate professor of pharmacology, and co-inventor Dr. Juan C. Collantes, post-doctoral research fellow at Rutgers Robert Wood Johnson Medical School, and has since been funding research in base editing at the University while undertaking its own evaluation and proof-of-concept studies. Horizon has a number of internal programs designed to accelerate the clinical uptake of this technology and is now seeking 35 partners to assess and shape the development of its Pin-point base editing platform.

Horizon will offer partners access to a novel system that could be used to progress more effective multi-gene knockout cell therapy programs through clinical development with an improved safety profile. Partners will also gain access to the Companys expertise in genome engineering of different cell types, access to early technical data, and influence over the direction of future development.

Base editing is a novel technology for engineering DNA in cells, which the potential to correct certain errors or mutations in the DNA, or inactivate disease-causing genes. Compared with currently available gene editing methodologies such as conventional CRISPR/Cas9, which creates "cuts" in the gene that can lead to adverse or negative effects, this new technology allows for accurate gene editing while reducing unintended genomic changes that could lead to deleterious effects in patients.

Dr. Jonathan Frampton, Corporate Development Partner, Horizon Discovery, said: "The technology could have a significant impact in enabling cell therapies to be progressed through clinical trials and towards commercialization. Horizon is pleased to offer an effective and precise base editing technology and, alongside Rutgers, aims to make base editing available to all appropriate cell and gene therapy companies as well as research departments. Partnering with leading organizations will help us to drive innovation and deliver the best therapy for the patient."

Dr. Shengkan 'Victor' Jin of Rutgers University stated: "The cytidine deaminase version of the technology alone could potentially be used for developing cell therapies such as gene modified cells for sickle cell anemia and beta thalassemia, HIV resistant cells for AIDS, over-the-shelf CAR-T cells for cancer, and MHC-compatible allogenic stem cells for transplantation. Other applications could include use as gene therapies for inherited genetic diseases including antitrypsin deficiency and Duchenne muscular dystrophy. In addition, we intend to take full advantage of the unique modularity and versatility features of Pin-point platform and develop efficient gene inactivation agents for potential treatment of many devastating diseases where the leading causal contributing factors are well defined. At the top of this disease list are Alzheimers disease, amyotrophic lateral sclerosis, and familial hypercholesterinemia."

Dr. S. David Kimball, Senior Vice President for Research and Economic Development at Rutgers University, added: "The gene editing technology developed by Rutgers has the potential to revolutionize how scientists think about their search for better options and outcomes in the treatment of disease. It has the potential to solve some of the most persistent global health challenges. This partnership with Horizon Discovery is paving the way to deliver biotherapies for precision medicine and diagnostics and improve human health. I am proud that Rutgers, together with Horizon, is among the frontrunners in the field of gene editing."

View source version on businesswire.com: https://www.businesswire.com/news/home/20200114005331/en/

Contacts

Zyme Communications (Trade and Regional Media) Lorna CuddonTel: +44 (0)7811 996 942Email: lorna.cuddon@zymecommunications.com

Read this article:
Horizon Discovery to Provide Access to Novel Base Editing Technology - Yahoo Finance

Posted in New Jersey Stem Cells | Comments Off on Horizon Discovery to Provide Access to Novel Base Editing Technology – Yahoo Finance

John Theurer Cancer Center Announces Appointment of Five New Physicians – Newswise

Posted: January 15, 2020 at 2:42 am

MEDIA CONTACT

Available for logged-in reporters only

John Theurer Cancer Center Announces Appointment of Five New Physicians

Cancer doctors bolster center's stem cell transplantation, blood cancer, and thoracic cancer programs.

Newswise HACKENSACK, N.J.,January 9, 2019 Five new physicians have joined the medical staff at John Theurer Cancer Center at Hackensack University Cancer Center in New Jersey:

Hyung C. Suh, MD, PhD, is a hematologist-oncologist who joined the Stem Cell Transplantation and Cellular Therapy program. Dr. Suh specializes in the care of people with blood cancers (such as leukemia, lymphoma, and multiple myeloma) and in the use of stem cell transplantation, cellular therapy, and immunotherapy to treat these cancers. He is also an experienced biomedical scientist with expertise in hematology-oncology research and the translation of research findings from the laboratory to the patients they may help. A native of South Korea, Dr. Suh graduated from Yonsei University College of Medicine in Seoul, where he earned his MD and PhD degrees. He completed internal medicine residencies at Yonsei University College of Medicine and Cleveland Clinic Foundation and hematology-oncology fellowships at Yonsei University College of Medicine and UCLA School of Medicine.

Gurbakhash Kaur, MD, is a hematologist-oncologist who specializes in hematology-oncology, especially the treatment of multiple myeloma. She is especially interested in the application of novel immunotherapies to treat cancer, including multiple myeloma. Dr. Kaur received her medical degree from Drexel University College of Medicine and completed her internal medicine residency at Tufts Medical Center. She then went on to complete a fellowship in hematology-oncology at Montefiore Medical Center.

Sukhdeep Kaur, MD, is a hematologist-oncologist who specializes in stem cell transplantation including allogeneic transplants (from a donor) and autologous ("self") transplants for blood cancers and blood diseases. She also oversees the use of cellular therapies in patients, including CAR T-cell therapy an innovative treatment which trains a patient's white blood cells (called T cells) to find and destroy cancer cells. Dr. Kaur received her medical degree from Ross University and completed her internal medicine residency at Drexel University College of Medicine, serving as Chief Resident in her final year. She then went on to complete a fellowship in hematology-oncology at Robert Wood Johnson University Hospital/Cancer Institute of New Jersey, where she was Chief Fellow.

Andrew Ip, MD, MS, is a hematologist-oncologist who specializes in the care of patients with lymphoma and multiple myeloma. In his research, Dr. Ip is part of John Theurer Cancer Center's Outcomes Division. He is interested in utilizing population science to see the "big picture" of cancer care in order to enhance the lives of patients and their families. He also has an interest in using digital health technology to promote improved cancer outcomes, having piloted an Apple Watch physical activity intervention for people with cancer. Dr. Ip received his medical degree from Jefferson Medical College (now Sidney Kimmel Medical College at Thomas Jefferson University). He completed his internal medicine residency at Emory University School of Medicine, where he was Chief Medical Resident in his last year. He then went on to complete a fellowship in hematology and medical oncology at the Winship Cancer Institute at Emory, where he was Chief Fellow for his final year.

Kaushal Parikh, MBBS, is a medical oncologist who specializes in the treatment of patients with thoracic cancers, such as lung cancer, thymoma, and mesothelioma. He is also involved in drug development and early-phase clinical trials, particularly through John Theurer Cancer Center's robust Phase I clinical trials program. He and his colleagues are working to expand the translational research program so that more findings from the laboratory can be translated to the clinic to help patients. Dr. Parikh received his medical degree from Topiwala National Medical College in Mumbai, India. He completed his internal medicine residency and hematology-oncology fellowship at New York Medical College, where he was Chief Hematology and Oncology Fellow for his final year. He then completed a fellowship in thoracic oncology at the Mayo Clinic School of Medicine in Minnesota.

For more information, contact Mary McGeever, Hackensack University Medical Center Communications and Public Relations Department, at 551-996-1730 (office), 551-795-1675 (cell) or Mary.McGeever@HackensackMeridian.org

ABOUTJOHN THEURER CANCER CENTERATHACKENSACKUNIVERSITY MEDICAL CENTER

John Theurer Cancer CenteratHackensack University Medical CenterisNew Jersey'slargest and most comprehensive center dedicated to the diagnosis, treatment, management, research, screenings, and preventive care as well as survivorship of patients with all types of cancers. The 14 specialized divisions covering the complete spectrum of cancer care have developed a close-knit team of medical, research, nursing, and support staff with specialized expertise that translates into more advanced, focused care for all patients. Each year, more people in theNew Jersey/New York metropolitan area turn toJohn Theurer Cancer Centerfor cancer care than to any other facility inNew Jersey. Housed withinHackensack University Medical Center, a 775-bed not-for-profit teaching, tertiary care, and research hospital, John Theurer Cancer Center provides state-of-the-art technological advances, compassionate care, research innovations, medical expertise, and a full range of aftercare services that distinguishJohn Theurer Cancer Centerfrom other facilities.For additional information, please visitwww.jtcancercenter.org.

About Hackensack Meridian Hackensack University Medical Center

Hackensack Meridian Hackensack University Medical Center, a 781-bed nonprofit teaching and research hospital located in Bergen County, NJ, is the largest provider of inpatient and outpatient services in the state. Founded in 1888 as the countys first hospital, it is now part of the largest, most comprehensive and truly integrated health care network in New Jersey, offering a complete range of medical services, innovative research and life-enhancing care, which is comprised of 35,000 team members and more than 7,000 physicians. Hackensack University Medical Center is ranked #2 in New Jersey and #59 in the country in U.S. News & World Reports 2019-20 Best Hospital rankings and is ranked high-performing in the U.S. in colon cancer surgery,lung cancersurgery,COPD, heart failure, heart bypass surgery, aortic valve surgery,abdominal aortic aneurysm repair, knee replacement and hip replacement. Out of 4,500 hospitals evaluated, Hackensack is one of only 57 that received a top rating in all nine procedures and conditions. Hackensack University Medical Center is one of only five major academic medical centers in the nation to receive Healthgrades Americas 50 Best Hospitals Award for five or more years in a row. Beckers Hospital Review recognized Hackensack University Medical Center as one of the 100 Great Hospitals in America 2018. The medical center is one of the top 25 green hospitals in the country according to Practice Greenhealth, and received 26 Gold Seals of Approval by The Joint Commission more than any other hospital in the country. It was the first hospital in New Jersey and second in the nation to become a Magnet recognized hospital for nursing excellence; receiving its sixth consecutive designation in 2019. Hackensack University Medical Center has created an entire campus of award-winning care, including: John Theurer Cancer Center, a consortium member of the NCI-designated Georgetown Lombardi Comprehensive Cancer Center; the Heart & Vascular Hospital; and the Sarkis and Siran Gabrellian Womens and Childrens Pavilion, which houses the Joseph M. Sanzari Childrens Hospital and Donna A. Sanzari Womens Hospital, which was designed with The Deirdre Imus Environmental Health Center and listed on the Green Guides list of Top 10 Green Hospitals in the U.S. Hackensack University Medical Center is the Hometown Hospital of the New York Giants and the New York Red Bulls and is Official Medical Services Provider to THE NORTHERN TRUST PGA Golf Tournament. It remains committed to its community through fundraising and community events especially the Tackle Kids Cancer Campaign providing much needed research at the Childrens Cancer Institute housed at the Joseph M. Sanzari Childrens Hospital. To learn more, visit http://www.HackensackUMC.org.

Link:
John Theurer Cancer Center Announces Appointment of Five New Physicians - Newswise

Posted in New Jersey Stem Cells | Comments Off on John Theurer Cancer Center Announces Appointment of Five New Physicians – Newswise

Horizon to provide access to novel base editing technology – SelectScience

Posted: January 15, 2020 at 2:42 am

Horizon Discovery, one of theglobal leaders in the application of gene editing and gene modulation technologies, announced that it will provide access to a novel base editing technology licensed from Rutgers, The State University of New Jersey, for exclusive use in therapeutic, diagnostic and services applications. This technology is incorporated into Horizons next-generation gene editing platform to enable the development of novel therapeutics that rely on engineering patients cells either directly in the body (gene therapy), or externally before transplanting back into the patient (cell therapy). This platform will also expand the companys research tools and service provisions.

The company formed an exclusive partnership with Rutgers in January 2019 to further develop the novel base editing technology invented by Dr. Shengkan Jin, associate professor of pharmacology, and co-inventor Dr. Juan C. Collantes, post-doctoral research fellow at Rutgers Robert Wood Johnson Medical School, and has since been funding research in base editing at the University while undertaking its own evaluation and proof-of-concept studies. Horizon has a number of internal programs designed to accelerate the clinical uptake of this technology and is now seeking 35 partners to assess and shape the development of its Pin-point base editing platform.

Horizon will offer partners access to a novel system that could be used to progress more effective multi-gene knockout cell therapy programs through clinical development with an improved safety profile. Partners will also gain access to the companys expertise in genome engineering of different cell types, access to early technical data, and influence over the direction of future development.

Base editing is a novel technology for engineering DNA in cells, which the potential to correct certain errors or mutations in the DNA, or inactivate disease-causing genes. Compared with currently available gene editing methodologies such as conventional CRISPR/Cas9, which creates cuts in the gene that can lead to adverse or negative effects, this new technology allows for accurate gene editing while reducing unintended genomic changes that could lead to deleterious effects in patients.

Dr. Jonathan Frampton, Corporate Development Partner, Horizon Discovery, said: The technology could have a significant impact in enabling cell therapies to be progressed through clinical trials and towards commercialization. Horizon is pleased to offer an effective and precise base editing technology and, alongside Rutgers, aims to make base editing available to all appropriate cell and gene therapy companies as well as research departments. Partnering with leading organizations will help us to drive innovation and deliver the best therapy for the patient.

Dr. Shengkan 'Victor' Jin of Rutgers University stated: The cytidine deaminase version of the technology alone could potentially be used for developing cell therapies such as gene modified cells for sickle cell anemia and beta thalassemia, HIV resistant cells for AIDS, over-the-shelf CAR-T cells for cancer, and MHC-compatible allogenic stem cells for transplantation. Other applications could include use as gene therapies for inherited genetic diseases including antitrypsin deficiency and Duchenne muscular dystrophy. In addition, we intend to take full advantage of the unique modularity and versatility features of Pin-point platform and develop efficient gene inactivation agents for potential treatment of many devastating diseases where the leading causal contributing factors are well defined. At the top of this disease list are Alzheimers disease, amyotrophic lateral sclerosis, and familial hypercholesterinemia.

Dr. S. David Kimball, Senior Vice President for Research and Economic Development at Rutgers University, added: The gene editing technology developed by Rutgers has the potential to revolutionize how scientists think about their search for better options and outcomes in the treatment of disease. It has the potential to solve some of the most persistent global health challenges. This partnership with Horizon Discovery is paving the way to deliver biotherapies for precision medicine and diagnostics and improve human health. I am proud that Rutgers, together with Horizon, is among the frontrunners in the field of gene editing.

Want more of the latest science news straight to you inbox? Become a SelectScience member for free today>>

See more here:
Horizon to provide access to novel base editing technology - SelectScience

Posted in New Jersey Stem Cells | Comments Off on Horizon to provide access to novel base editing technology – SelectScience

Reviewing Phibro Animal Health (NASDAQ:PAHC) & AgeX Therapeutics (NASDAQ:AGE) – Riverton Roll

Posted: January 15, 2020 at 2:42 am

AgeX Therapeutics (NYSE:AGE) and Phibro Animal Health (NASDAQ:PAHC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, profitability, institutional ownership and valuation.

Profitability

This table compares AgeX Therapeutics and Phibro Animal Healths net margins, return on equity and return on assets.

Risk & Volatility

AgeX Therapeutics has a beta of 4.42, indicating that its stock price is 342% more volatile than the S&P 500. Comparatively, Phibro Animal Health has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for AgeX Therapeutics and Phibro Animal Health, as provided by MarketBeat.com.

Phibro Animal Health has a consensus price target of $26.60, indicating a potential upside of 5.18%. Given Phibro Animal Healths higher possible upside, analysts plainly believe Phibro Animal Health is more favorable than AgeX Therapeutics.

Insider and Institutional Ownership

17.7% of AgeX Therapeutics shares are owned by institutional investors. Comparatively, 50.5% of Phibro Animal Health shares are owned by institutional investors. 3.1% of AgeX Therapeutics shares are owned by company insiders. Comparatively, 50.1% of Phibro Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares AgeX Therapeutics and Phibro Animal Healths revenue, earnings per share and valuation.

Phibro Animal Health has higher revenue and earnings than AgeX Therapeutics.

Summary

Phibro Animal Health beats AgeX Therapeutics on 9 of the 11 factors compared between the two stocks.

About AgeX Therapeutics

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of therapeutics for age-related degenerative diseases in the United Stated. The company is developing AGEX-BAT1 and AGEX-VASC1, which are cell-based approaches in the preclinical stage of development to correct metabolic imbalances in aging; and to restore vascular support in ischemic tissues. It is also involved in the development of AGEX-iTR1547, a drug-based formulation in preclinical development for restoring regenerative potential in various aged tissues afflicted with degenerative diseases. In addition, the company develops Renelon, a first-generation tissue regeneration product designed to promote scarless tissue repair. Further, it markets genomic interpretation algorithms; and Cytiva, including pluripotent stem cell derived heart muscle cells used in screening drugs for efficacy and safety. The company was founded in 2017 and is based in Alameda, California. AgeX Therapeutics, Inc.(AMEX:AGE) operates independently of BioTime, Inc. as of November 28, 2018.

About Phibro Animal Health

Phibro Animal Health Corporation operates as a diversified animal health and mineral nutrition company primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its animal health products also comprise antibacterials that are biological or chemical products used in the animal health industry to treat or to prevent diseases; anticoccidials primarily used to prevent and control the disease coccidiosis in poultry and cattle; anthelmintics to treat infestations of parasitic intestinal worms; and anti-bloat treatment products for cattle to control bloat in animals grazing on legume or wheat-pasture. In addition, the company offers nutritional specialty products, which enhance nutrition to help improve health and performance; and vaccines to prevent diseases primarily for the poultry and swine markets. Further, it manufactures and markets formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds; and various specialty ingredients for use in the personal care, industrial chemical, and chemical catalyst industries. The company sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle integrators, as well as through commercial animal feed manufacturers, wholesalers, and distributors. It also operates in Israel, Latin America, Canada, Europe, Africa, and the Asia/Pacific. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. The company is headquartered in Teaneck, New Jersey. Phibro Animal Health Corporation is a subsidiary of BFI Co., LLC.

Receive News & Ratings for AgeX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AgeX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

View original post here:
Reviewing Phibro Animal Health (NASDAQ:PAHC) & AgeX Therapeutics (NASDAQ:AGE) - Riverton Roll

Posted in New Jersey Stem Cells | Comments Off on Reviewing Phibro Animal Health (NASDAQ:PAHC) & AgeX Therapeutics (NASDAQ:AGE) – Riverton Roll

The Past and the Future of the Earths Oldest Trees – The New Yorker

Posted: January 13, 2020 at 8:46 pm

About forty-five hundred years ago, not long after the completion of the Great Pyramid at Giza, a seed of Pinus longaeva, the Great Basin bristlecone pine, landed on a steep slope in what are now known as the White Mountains, in eastern California. The seed may have travelled there on a gust of wind, its flight aided by a winglike attachment to the nut. Or it could have been planted by a bird known as the Clarks nutcracker, which likes to hide pine seeds in caches; nutcrackers have phenomenal spatial memory and can recall thousands of such caches. This seed, however, lay undisturbed. On a moist day in fall, or in the wake of melting snows in spring, a seedling appeared above grounda stubby one-inch stem with a tuft of bright-green shoots.

Most seedlings die within a year; the mortality rate is more than ninety-nine per cent. The survivors are sometimes seen growing in the shadow of a fallen tree. The landscape of the Ancient Bristlecone Pine Forest, as this area of the White Mountains is called, is littered with fragments of dead treestrunks, limbs, roots, and smaller chunks. Pinus longaeva grows exclusively in subalpine regions of the Great Basin, which stretches from the eastern slopes of the Sierra Nevada to the Wasatch Range, in Utah. Conditions are generally too arid for the dead wood to rot; instead, it erodes, sanded down like rock. The remnants may harbor nutrients and fungi that help new trees grow. Bristlecones rise from the bones of their ancestorsa city within a cemetery.

Coast redwoods and giant sequoias, Californias gargantuan world-record-holding trees, can grow fifty feet or more in their first twenty years. Bristlecones rise agonizingly slowly. After four or five years, the seedling on the steep slope would have been just a few inches higher, sprouting needles in place of the embryonic shoots. The needles are a deep green, tough, resinous, and closely bunched, in groups of five. On a mature tree, they live for fifty years or more. Decades may have passed before the tree was human height, and decades more before it resembled a conventional pine. Bristlecone saplings grow straight up, with relatively sparse foliage, looking like undernourished Christmas trees. After a few hundred yearsby which time the Old Kingdom of Egypt had fallenit was probably forty or fifty feet in height.

Many tree species live for hundreds of years. A smaller but not inconsiderable number, including the sequoias and certain yews, oaks, cypresses, and junipers, survive for thousands. Once a bristlecone has established itself in the unforgiving conditions of the White Mountains, it can last almost indefinitely. The trees tend to grow some distance from one another, so fires almost never destroy an entire stand. Because only a few other plant species can handle the dry, cold climate, the bristlecones face little competition. Unlike most plants, they tolerate dolomite soil, which is composed of a chalky type of limestone that is heavily alkaline and low in nutrients. As for insect threats, bristlecone wood is so dense that mountain-pine beetles and other pests can rarely burrow their way into it.

Empires rose and fell; wars raged; people were enslaved and freed; and the tree from 2500 B.C. continued its implacable slow-motion existence, adding about two-hundredths of an inch to the diameter of its trunk each year. Minute changes in the tree-ring record make bristlecones an exceptionally useful source of data about changing conditions on earth. When rains are heavier than normal, the rings widen. When volcanic eruptions cause global cooling, frost rings make the anomaly visible. The precision of these records means that bristlecones have periodically butted into other disciplines: geology, archeology, climatology. In the nineteen-sixties and seventies, the trees contributed to the upending of the canonical theory that Bronze Age civilization had spread westward from Egypt and the Near East. Bristlecones have also affected modern political discourse: the famous hockey stick graph, which two decades ago raised awareness of human-driven global warming, relied on bristlecone data.

As the millennia go by, bristlecones become contorted and wraithlike. The main stem, or leader, dies back. Entire branches, even the trunk itself, become fossils. At first glance, the tree may look dead. Such is the case of the forty-five-hundred-year-old tree that clings to life near the tourist path that now runs through the Ancient Bristlecone Pine Forest. Spears of dead wood jut into the air. The trunk is a marbled hulk stripped of bark, like driftwood thrown from a vanished ocean. A ribbon of live bark runs up one side, funnelling water and nutrients to clumps of green needles high above. All told, the tree is an unprepossessing specimen; most people march past it without giving it a second glance. When I sat by the tree for an hour last July, the only visitor who took any notice of it was a dog named Dougie, who briefly sniffed the trunk and then darted away.

In 1957, Edmund Schulman, a researcher from the Laboratory of Tree-Ring Research, in Tucson, determined that this eccentric senior was older than any other tree on earth which had been dated. He named it Methuselah. The next year, when the United States Forest Service established the Ancient Bristlecone Pine Forest, Methuselah bore an identifying marker. The sign was soon removed, however, because tourists were extracting souvenirs. The trees location is now known only to scientists, forest rangers, and a few enthusiasts. This anonymity is just as well, since there are almost certainly Great Basin bristlecones that are yet older. A nearby tree appears to have been born about three hundred years earlier. Even more ancient trees are rumored to exist elsewhere in the Whites.

What is most astonishing about Pinus longaeva is not the age of any single organism but the collective oldness and otherness of its entire community. No two super-elderly trees look alike, to the point where they have acquired the characteristics of individuals. Trees are prone to anthropomorphism; we project our dreams and our anxieties onto them. Bristlecones have been called elders, sentinels, sages. The possibility that climate change will cause their extinction has inspired a spate of alarmed news stories, although tree scientists tend to discount the idea that the bristlecones are in immediate danger. They have survived any number of catastrophes in the past; they may survive humanity.

Hope youve read up on the curse of the bristlecone, Andy Bunn told me, with mock concern, over breakfast at a diner in Bishop, California. We were joined by Matt Salzer, a veteran researcher from the Laboratory of Tree-Ring Research. Bunn, who teaches environmental science at Western Washington University, in Bellingham, has been working with bristlecones since 2006. People who get too close to these trees die young, he explained. Edmund Schulman, the man who discovered Methuselah, died, of a stroke, at the age of forty-nine. Bunn went on, Matt here has a slab of the Currey Treeanother well-known specimenin his office. He handles it with abandon, as if it wont kill him.

Bristlecone pines thrive at high elevations and live for thousands of years.

Salzer sighed. Yeah, the curse, he said. Always thought it was stupid. Had second thoughts when I had to get that stent put in.

They laughed and dug into their breakfast. Both come from academic families on the East Coast: Bunn, who is forty-eight, is the son of a distinguished hematologist at Harvard Medical School; Salzer, who is fifty-eight, grew up in Buffalo, the son of an education professor. Bunn and Salzer now affect the outdoorsy aesthetic of eastern California: flannel shirts, vests, cargo pants.

It was mid-September, California fire season, and the diner was crowded with firefighters on call. Bishop is the largest town in Owens Valley, which lies between the Sierra Nevada and the White Mountains. The Sierras loom dramatically over the plain, their gray granite peaks etched in the sun. The Whites present a less impressive appearance from afar. Although they rise more than fourteen thousand feet, almost as high as the Sierras, they are smoother and more rounded, their slopes an unphotogenic beige. The bristlecone zone lies at an elevation of between nine and eleven thousand feet.

Bunn and Salzer had come to the Whites to lay the groundwork for a study of very old bristlecone wood. Bunn is keenly interested in tracking climate change through bristlecone data. Salzer has long wanted to fill out a comprehensive chronology of bristlecone tree rings, carrying on work that began at the Laboratory of Tree-Ring Research in the mid-twentieth century. After breakfast, we drove up a narrow, twisting road leading into the Whites. Upon picking a camping spot, we headed to the chief attraction of the Ancient Bristlecone Pine Forest: the Schulman Grove. It includes Methuselah, and was named for Edmund Schulman.

Bunn, the more loquacious of the pair, said, What is the oldest tree? Its trivia. Matt and I dont find it that interesting. Its unanswerable. A lot of these trees have been dated; a whole lot havent. He paused. Of course, I get a chill from standing next to something thats been living in the same place for five thousand years. We cant begin to comprehend the mechanisms of birth and death on that scale.

Salzer grunted assent: Yeah, theres a lot thats unknown. Soft-spoken and laconic, he tends to wait several long seconds before answering questions, and then says something on the order of Possibly, Not necessarily, or Unclear.

At the Schulman Grove, Bunn and Salzer met up with a group of European researchers. Tom De Mil, of Ghent University, was experimenting with making CT scans of tree-ring samples. He hoped that mapping differences in the density of the wood would yield an even more precise record of moisture and temperature variations from year to year. Jesper Bjrklund and Kristina Seftigen, who work in the Forest Dynamics department of the Swiss Federal Research Institute, had developed sophisticated new models for extracting historical climate data from tree-ring cells.

We all began walking the tourist path, and the slope rising to our left presented a typical bristlecone habitat: trees more or less evenly spaced, with the bright-tan hulks of dead trees intervening. It looked less like a forest than like a poorly managed orchard. But dark-green junior bristlecones, on all sides of us, confirmed the general health of the population.

Bunn stepped over an exposed root and said, You see the roots going all over the placeabove ground, below ground. Theyll often go uphill. They find the cracks in the substrate, work their way into it.

Salzer added, Therell be a period of time in spring when snow will melt during the day, giving all the trees a drink, then freeze up at night and melt again the next day. Its like a watering system, until the snow is gone.

De Mil picked up a remnant and pointed out a thin crack running through it. Frost ring, he said. Is this one of the major events?

Salzer looked, pondered, and said, Could be.

When a significant volcanic eruption occurs, the volume of matter and dust ejected into the atmosphere can obscure the sun and cause a worldwide cooling; at such times, freezing temperatures arrive unseasonably early, when cells in a new layer of wood are still forming. The resulting damage to the cells causes a break in the usual succession of ringsa frost ring.

A few events are so severe that they show up in every tree, Salzer said. 2036 B.C., 43 B.C., 627 A.D. He went on, 2036 B.C. is maybe my favorite. Its also my bane, because there is hardly any wood left that has intact rings on either side of that date. The wood fractures, and erosion sets in.

Bunn noted, These volcanic events have been linked to disruptions of early civilizations, like Akkad, the worlds first empire. The poem The Curse of Akkad tells of how the harvests failed and the population starved. People were flailing at themselves from hungerthat kind of thing.

And 43 B.C., after the assassination of Caesar, Salzer said. People thought that the darkening of the skies was a message from the gods. Julius Caesar died in 44 B.C. According to Plutarch, the sun was obscured for an entire yearits orb rose pale and without radianceand fruits withered. Records of the Han dynasty, in China, indicate that in the same period the sun was bluish white and cast no shadows. The most commonly cited cause is a volcanic cloud emanating from Mt. Etna, in Sicily, although other eruptions have been proposed.

We stood for a moment looking at the trees. They did seem sentinel-like. Bunn touched a neighboring branch, which fell into an easy, swinging motion.

Andy likes to feel the energy from the trees, Salzer said, gently snickering. He was a bit of a bristlecone himself: deliberate, diffident, bemused.

We continued following the path, which traces a four-mile route through the forest. Bunn, equipped with a G.P.S. device, searched for a site, off the path, where five- or six-thousand-year-old remnants could be found. Salzer was on the lookout for Methuselah. After a brief search, he identified the tree, giving it a friendly pat.

Two husky, weathered Welshmen happened alongone dressed all in black, including a black leather cap, and the other wearing a red flannel shirt. You lot look like experts, one of them said. Do you know which is Methuselah?

Turn around, Bunn said.

The Welshmen looked and laughed.

This? they said.

The University of Arizonas Laboratory of Tree-Ring Research, where secrets of the bristlecone reside, was founded in 1937. For decades, it occupied a warren of rooms and corridors beneath a football stadium. Since 2013, the lab has been housed in a handsome building with an exterior of hanging metal columns, giving it the look of an abstract forest. Inside, researchers have access to a kind of arboreal Library of Congress: a vast collection of tree fragments from around the world, including cross-sections of giant sequoias. The lab is affixing each with a bar code, so that researchers can check out samples.

The lab was the brainchild of Andrew Ellicott Douglass, an astronomer who, in 1904, began collecting tree samples in the West, convinced that variations in ring width could reveal cycles of solar activity. His research remained inconclusive, but along the way he essentially founded dendrochronology, the science of tree-ring dating. His greatest insight was to recognize patterns among the hundreds of samples he gathered in Arizona: rings on the trees were wider in 1884 and 1885, narrower in 1851, and so on. Using a giant-sequoia stump as a reference, Douglass meticulously built up a tree-ring chronology, reaching back to around 1300 B.C. Stray fragments of wood could be matched to the master index. Douglass employed this system to develop fairly exact dates for Aztec and Ancestral Puebloan ruins in the American Southwest.

At the turn of the twentieth century, the giant sequoias, which grow only on the western slopes of the Sierras, were widely assumed to be the worlds oldest trees. They were certainly the biggest: the General Sherman Tree, in Sequoia National Park, is the most voluminous on earth. (In the late nineteenth century, it was known as the Karl Marx Tree, because a leftist commune occupied the area.) Bristlecones, by comparison, seemed to be mere oddities. John Muir, the pioneering naturalist, described them as irrepressibly and extravagantly picturesque. Then, in the nineteen-forties, a Forest Service ranger named Al Noren counted the rings on bristlecones and began to suspect their true age. Word reached Edmund Schulman, Douglasss second-in-command.

Schulman first visited the Whites in 1953 and discovered Methuselah four years later. He dated the trees with a time-tested method: using a coring device to bore in and extract a very thin sample. The process causes mature trees no harm. The naked eye can glean little from a core; you need a microscope to see the rings clearly and pinpoint differences. Schulman wrote an overview of his work for National Geographic, titling it Bristlecone Pine, Oldest Known Living Thing. He died just before the issue was published.

Chatter about a bristlecone curse started after the tragic demise of the so-called Prometheus Tree, which Salzer prefers to call the Currey Tree. In 1964, a graduate student named Donald Currey was attempting to date a huge bristlecone on Wheeler Peak, in the Snake Range, in Nevada. Currey first tried to take a core, but he had trouble getting a good sample. With the permission of the Forest Service, he decided to cut down the entire tree. A crew showed up with a chain saw, but when the foreman touched Prometheus he reportedly said, Im not cutting this tree. The next day, another crew did the deed. Currey concluded that the tree was forty-nine hundred years oldslightly older than the bristlecones Schulman had studied in the Whites. Currey had to live with the reputation of having, in the words of one writer-activist, casually killed (yes, murdered!) the worlds oldest tree. A year after Prometheus was felled, a young Forest Service employee suffered a fatal heart attack while attempting to remove a slab.

Five years ago, the Los Angeles-based artist Jeff Weiss organized a memorial service for Prometheus, on the occasion of the fiftieth anniversary of its death. Matt Salzer, despite his resistance to mythologizing bristlecones, recorded a speech for the gathering. He spoke of how remnants of bristlecones, including the detritus of Prometheus, reveal how climate has changed in the past and how it might change in the future. He said, It is almost as if the trees are speaking the words of the Welsh poet Dylan Thomas, who once wrote, I have heard many years of telling, / And many years should see some change.

Some of the bones of Prometheus are squirrelled away in Salzers office in Tucson. When I stopped by, not long after our trip to the White Mountains, several slabs were resting next to a filing cabinet. Salzer arranged them end to end, forming a six-foot radius. He rummaged around for more bristlecone relics, and found a remnant with a ring marked 43 B.C.the frost ring that followed Caesars death.

We also looked at three cores from Methuselah and four from a tree that Salzer calls Harlans Secret Tree, for Tom Harlan, a dendrochronologist who began working at the Laboratory of Tree-Ring Research in 1957. Some years after Schulmans death, Harlan examined his predecessors stock of cores and realized that one tree was even older than Methuselah. Salzer provisionally estimates, based on Harlans core samples, that the tree is 4,817 years old. He would like to verify that figure, but hes not sure precisely where Harlans Secret Tree is. Harlan died in 2013, and did not record its location. There is a clue, though, in the form of a page from Edmund Schulmans original 1957 notes.

Salzer hopes to resolve the matter, if only to satisfy periodic calls from Guinness World Records. But he is more excited by the possibility of filling in the remaining gaps in the master bristlecone chronology, which extends back ten thousand years. In addition, he is exploring the complex relationship between bristlecone rings and radiocarbon dating. His partner on the project is Charlotte Pearson, a forty-three-year-old British archeologist, who took up dendrochronology because she was fascinated by its potential implications for the history of ancient civilizations.

Pearson stopped by Salzers office to discuss their collaboration. What we want to do is get the best possible calibration, she said. Make it high-resolution. Many people tend to think that a radiocarbon curve is set in stonethat once you get a date you can trust in it completely. But the curve has been revised many times, and the bristlecones have been crucial to that process.

Radiocarbon is an isotope of carbon that is generated in the earths atmosphere by cosmic radiation. All living things consume small quantities of the isotope as they take in carbon dioxide. When they die, the radiocarbon in their remains steadily decays. In 1949, the chemist Willard Libby announced a remarkable discovery: the age of any organic remnant can be determined by measuring the level of radiocarbon against what a living thing typically maintains. In a stroke, radiocarbon allowed for a comprehensive dating of relics from human civilization and biological history.

A typical bristlecone habitat features trees that are more or less evenly spaced, with the hulks of dead trees intervening. It looks less like a forest than like a poorly managed orchard.

Libby, who won a Nobel Prize for his work, was aware that his model relied on an untested assumptionthat the level of radiocarbon in the atmosphere remains constant. In the sixties, the Austrian-born geophysicist Hans Suess took radiocarbon data from some very old bristlecone samples, knowing that ring-counting had established their age precisely. The radiocarbon-dating estimate was way off, giving the impression that the samples were many hundreds of years younger than they were. Suess concluded that levels of radiocarbon had been considerably higher five or six thousand years ago, perhaps because of increased solar activity or shifts in the earths magnetic field. As a result, archeological dates in the period between 4000 and 2000 B.C. had to be drastically revised. The recalibration was especially dramatic in the case of Neolithic ruins in remote parts of Western Europe, for which no other historical documentation existed. These sites were assumed to have postdated the Bronze Age architecture of Mesopotamia and Egypt; instead, they came first.

The bristlecones werent done with their meddling. In 2018, Pearson, Salzer, and others published a paper in which they tried out a new approach. Prior research had calibrated the curve on a decade-to-decade basis; Pearson and Salzer broke it down year by year. It was time-consuming work, and they limited their study to the period from 1700 to 1500 B.C. These dates were not chosen at random: Pearson had long been obsessed with the giant volcanic eruption that took place on the island of Thera, in the Santorini archipelago. It was initially thought, on the basis of historical records, that the Thera event had contributed to the fall of the Minoan civilization, but radiocarbon dating of an olive branch placed the eruption several decades earlier, at a time when the Minoans were thriving. Pearson and Salzer believe that the date of the eruption should be moved forward. A bristlecone frost ring from 1560 B.C. is now considered to be a strong candidate for the temporal marker of the Thera cataclysm.

Pearson said of the Thera revision, This is from only two hundred years of our proposed ten-thousand-year annual chronology. We expect more surprises. For example, theres the business of Miyake Events. In 2012, a solar scientist named Fusa Miyake used tree rings to pinpoint an enormous jump in radiocarbon, from 774 to 775 A.D. It appears to have been a huge solar event.

Salzer fingered one of the cores of Methuselah, which were still on his desk. The event didnt do any apparent harm to the trees or anything else, he said. No frost rings or anything like that. But people are very interested in the mechanics of such events today, because if one happened tomorrow He made a Kablooey! gesture in the direction of his computer.

I asked Salzer how scientists in other disciplines had reacted to periodic disruptions from the bristlecone community.

Well, in the sixties one Old World archeologist said something like: Why should we be concerned with whats happening with some shrub in California? But with our Thera paper the archeologists seemed pretty happy. These new dates were a better fit with what theyd suspected all along.

Like the Ents, in The Lord of the Rings, the bristlecones seem to be imparting information slowly, on their own time.

Something that began growing at the time of the Pyramids has a right to say stuff, Pearson said. It gets to comment.

The oldest bristlecones in the White Mountains live in a lower-altitude ravine on a north-facing slope. At higher altitudes, the trees thin out as they get near an exposed ridge. A few lone trees, usually younger, stand ahead of the pack, like scouts. They make you wonder about the bristlecones future. Are they creeping up the slopes, in reaction to a warming earth?

The matter of whether the trees record anthropogenic change was once the subject of furious debate. In 1998, the climatologist Michael E.Mann published the hockey stick graph, showing a steep rise in global mean temperature from about 1850 onward. Manns paper was co-authored by Malcolm Hughes, a senior researcher at the Laboratory of Tree-Ring Research, and depended heavily on bristlecone chronologies. Scientists, however, knew that bristlecones at lower altitudes were a less reliable index of temperature fluctuation: it was only on the exposed upper edge of the tree line that the trees were highly sensitive to a blast of cold, and more likely to develop frost rings and other markers of extremity. Climate-change deniers claimed fraud and spoke darkly of a bristlecones addiction. Subsequent papers by Hughes, Salzer, and others refined the models, focussing on the upper-tree-line samples. The new models, together with an avalanche of data from other sources, confirm the hockey-stick upswing.

Bristlecones have been through hot spells before. Circa 4000 B.C., during the mid-Holocene period, the earth was about one degree Celsius warmer than it is today. But it is on track to get hotter than that. What happens when the bristlecones move up so far that they run out of space? A 2007 paper by the geologist Christopher Van de Ven paints a bleak picture. If the earth were to warm by two degrees, the Schulman Grove would die off. At six degrees, bristlecones would be confined to the highest slopes of White Mountain Peak. In such a scenario, that would be the least of our problems: a six-degree warming would be catastrophic in countless other ways.

On a midsummer trip to the Whites, I met up with Brian Smithers, a forty-three-year-old ecologist from Montana State University, in Bozeman. He is a rising star of bristlecone studies, and not uncontroversial. He grew up in a small town in the Sierras and turned to the natural sciences after abandoning plans of becoming an astronaut. A trim athlete who competes in triathlons, he was accepted into the U.S.Air Force Academy, but decided not to go when he realized that he might have to kill people. Instead, he served in the Peace Corps in Fiji. When he returned home, he became an ornithologist; in the past decade, he has shifted to tree science.

I met Smithers while he was organizing a summertime survey by an organization known as GLORIA Great Basin. It is part of a worldwide network of GLORIA groupsGlobal Observation Research Initiative in Alpine Environmentswhich study how alpine species respond to climate change. Several dozen volunteersecologists, botanists, amateur enthusiastsscoured high-elevation sites in the Whites, counting small alpine plants in gridded-off areas. I tagged along, though I could barely follow the conversation, which was conducted largely in Latin: Is this Trisetum spicatum? That Oxytropis is a real cutie.

Smithers took part of a day off to show me a site where he had done a study comparing bristlecone populations with those of the limber pine, another hardy species that grows at high altitudes. He and other researchers had noted that in this area the limber pines appeared to be outpacing the bristlecones in moving to higher elevationsleap-frogging over them. His paper, published in 2017, attracted media attention, resulting in headlines like: ANCIENT BRISTLECONE PINE FORESTS ARE BEING OVERWHELMED BY CLIMATE CHANGE (the Los Angeles Times) and CLIMATE CHANGE COULD KILL THE WORLDS OLDEST TREES (Live Science).

It got away from me a little bit, Smithers said, as we trudged across a rock-strewn meadow toward a distant ridge. Its hard to make a complex point in limited space. I was talking about some local populations where bristlecones were in trouble. The problem is that we cant begin to observe change at the rate these trees are accustomed to. At the moment, these limber pines appear to be charging up the slope. But maybe they will all die in fifty years, and maybe thats when bristlecones will move in.

We reached a ridge where dead bristlecones were scattered about in large numbersa relict grove. Trunks and branches protruded into the air, their surfaces polished and smooth to the touch. Small fragments with grayish, scoured wood lay in the low brush. Something happened here, Smithers said. These were really old trees that lived through a lot of really crappy conditions. Theres no sign of a fire. No sign of insects. So what killed them?

On the other side of the ridge, bristlecones reappeared. Check out this one, Smithers said, pointing to an apparently long-dead hunk of a tree. It looked as though it had been blown over in a storm, but tufts of green needles emerged from a branch on one side. A vein of live bark snaked around the dead trunk and disappeared into the ground. It was like a vine growing on a ruin, except that the ruin was itself.

We headed back to the Crooked Creek Station, a handsome, spartan pine-log facility where the GLORIA group was based for the week. Part of the complex had once stood in downtown Los Angeles, housing the Starlight Bar and Grill. In the late eighties, the University of California at Davis dismantled the structures and hauled them up into the Whites. Before Crooked Creek became a research station, in 1978, it had been a U.S.Navy outpost, where research was conducted into the physiological effects of high-altitude exposure. Reportedly, harbor seals were brought to a pond near the siteto what end one dare not imagine.

Dinner was served in the high-ceilinged common room at Crooked Creek. In the group was Connie Millar, a revered ecologist who has long worked for the Forest Service and who is responsible for launching GLORIA in North America. She has been studying the effects of climate change for decades, with the Great Basin as her favorite site of observation. She worked on bristlecones for years but has added other subjects of study, including the pika, an adorable rabbit-like mammal that thrives in mountain zones.

Im actually not too worried about the bristlecones, Millar told me. Schulman talked about longevity through adversity, and theres something to that. You cant look only at the upper tree line. Contrary to what the Van de Ven model suggests, trees are still growing at lower elevations, sometimes even below the current tree lines. You have to be aware of all these microclimates where temperature and moisture can vary in unexpected ways. All through the Great Basin you see this kind of endurance. I see it in the pikas, too. They make their habitats in the talusthe pile of rocky debris at the base of a slope or cliffand they find a mode of circulation almost decoupled from the outside. They hole up in their little air-conditioned homes.

Yet Millar is hardly sanguine about environmental threats to the trees. She told me that a colleague, Barbara Bentz, had recently found worrisome evidence of mountain-pine beetles killing bristlecones on Telescope Peak, in Death Valley. Such an invasion was previously thought to be impossible, because of the toughness of the trees wood. Whatever the fate of the bristlecones, she noted, the general global trends are catastrophic. The bristlecones live in their own world, she said. Their longevity seems to be related in mysterious ways to the length of time dead wood stays in the environment. Its hard to generalize from that.

Humans tend to make a cult of trees. Many ancient traditions posit the existence of a primal tree that embodies eternal life. Reverence surrounds the Bodhi Tree, in Bodh Gaya, India; the Cypress of Abarkuh, in Iran; the Hibakujumoku trees, in Hiroshima, which withstood the atomic blast. There are trees of life, and trees of death. In Schuberts song Der Lindenbaum, from the death-haunted cycle Winterreise, a linden tree calls to a disconsolate wanderer, Come to me, friend, / Here you will find rest. Thomas Mann makes much of that song in The Magic Mountain, finding it symbolic of a civilization hurtling toward its own destruction.

The bristlecone cult is varied and intense. Artists tease ghostlike figures from their writhing shapes. Creationists have tried to reconcile the bristlecones with a putative cosmological starting date of 4004 B.C. (Methuselah fits their chronology, but the older remnants have to be discarded.) The Long Now Foundation, a futuristic organization based in San Francisco, bought land in the area of Mount Washington, Nevada, in large part because it contained bristlecone pines. Jeff Bezos, a member, is funding the construction of a clock, in a mountain in Texas, that will tick for ten thousand years. Long Now hopes to erect a similar clock on Mt. Washington.

Tree worship can fall prey to political exploitation, especially when a national or ethnic group claims an immemorial attachment to a patch of land. Jared Farmer, in his 2013 book, Trees in Paradise: A California History, notes that Californias sequoias and redwoods were long lauded as emblems of American greatness. Madison Grant, one of the founders of the Save the Redwoods League, was a racist and a eugenicist, notorious for the best-selling 1916 tract The Passing of the Great Race. Grant extolled the giant trees in much the same terms that he applied to sturdy specimens of Nordic supremacy. The age of the trees allowed for a kind of backdating of Manifest Destiny, into the mists of prehistory.

Bristlecones cant be monumentalized in the same way. They have the look of survivors, not conquerors. Fittingly, they found fame during the Cold War, when atomic tests were taking place not far off, in the Nevada desert. Bristlecones are post-apocalyptic trees, sci-fi trees. They can be seen as symbols of our own precarious future. Michael P.Cohen, in his 1998 book, A Garden of Bristlecones, deftly anatomizes this latter-day bristlecone mythology, writing that the trees always reveal the motives of their observers.

My own bristlecone obsession is probably rooted in a fixation on extremely old people and things. Some of my favorite music was written centuries ago. When I was a teen-ager, I spent a summer wandering the Highlands and islands of Scotland, looking at Neolithic ruins as old as Methuselah. Meeting people with long memories gives me an elemental thrill. In 1990, when I was in college, I spoke on the phone to the Russian-born musical polymath Nicolas Slonimsky, who recalled walking the streets of Petrograd on the first day of the Bolshevik Revolution. I saw nothing, and went back to practicing the piano, he said.

In November, just before the first snows shut down access to the Whites, I made a final trip to the Schulman Grove. The question of the oldest tree nagged at me. Salzer had shown me the notebook page in which the location of Harlans Secret Tree is indicatedsomewhat opaquely. As on a treasure map, one is told to walk a certain distance and in a certain direction. Salzer and Bunn had followed the instructions and texted me a picture of a likely candidate. Next summer, Salzer plans to take a core sample and resolve the issue.

When I reached the site, I became convinced that a neighboring tree was a better match for Schulmans vague description. I basked for a while in the aura of this nameless ancient. Then I found a metal I.D. plate affixed to one of its roots. Checking the number against documentation in my notes, I was disappointed to find that the tree was only three thousand years old. I went back to Salzers tree, which had no visible tag. It was a heftier, healthier-looking specimen than Methuselah. The boughs were a vivid green and soft to the touch. Red-purple pollen cores were forming at many of the tips.

Was this it? Did it matter? I remembered a conversation that Id had with Tim Forsell, who manages the Crooked Creek Station in the summers. He said, Its so arrogant to think that we stumbled in there and happened to find the worlds oldest tree. Harlan always said there were older ones. I once asked him, If these trees can be five thousand years old, could there be six-thousand-year-old trees? And he answered, Absolutely.

By the time I headed back, night was falling. Light fades fast in the mountains, and I walked the last mile to the parking lot in near-darkness. But then a full moon rose, and the dolomite on neighboring slopes began to glow eerily bright, like phantom drifts of snow. The wind picked up and elicited a low, full whoosh from bristlecone branches, which swung to and fro without creaking or rustling. When the wind stopped, the forest felt like a cavernous but soundproofed spacea silent concert hall, an empty cathedral. The moon lit up the mountains as I drove to the valley below.

Excerpt from:
The Past and the Future of the Earths Oldest Trees - The New Yorker

Posted in Montana Stem Cells | Comments Off on The Past and the Future of the Earths Oldest Trees – The New Yorker

At the Crossroads of Art and Biotech, a Warning: Be Careful What You Wish For. – INDY Week

Posted: January 13, 2020 at 8:45 pm

ARTS WORK IN THE AGE OF BIOTECHNOLOGY: SHAPING OUR GENETIC FUTURES

Through Sunday, March 15

The Gregg Museum of Art & Design, Raleigh

Where do we draw the lines dividing art from science, natural from unnatural, and boldness from hubris?

An exhibit at N.C. States Gregg Museum of Art & Design doesnt answer these questions. Instead, it offers head-spinning new ways to ask them at the nexus of art and biotechnology, sharpening our insight into the fields future and expanding our understanding of it into the past.

These hard-to-classify collaborations between artists and scientistsseethe with hot-button issues related to ethics, privacy, human nature, and more. But if they have one message in common, its to be careful what you wish for.

Arts Work in the Age of Biotechnology: Shaping Our Genetic Futures is the result of more than two years of planning led by Molly Renda, the exhibit program librarian at N.C. State University Libraries, and the universitys Genetic Engineering and Society Center. Guest-curated by Hannah Star Rogers, who studies the intersection of art and science, the main exhibit at the Gregg has annexes in Hill and Hunt libraries.

On a recent tour of the exhibit, Renda and Fred Gould, the co-director of the GESC, said that they wanted to bring artists into the welter of science-and-design innovation taking place at the university because their differing perspectives on fundamental human issues create balance, tension, and discovery.

In the course of this, Ive found that artists tend to be more dystopian and designers are more utopian, Renda says.

There are different ways of knowing things, Gould adds. Thats why Molly came up with the name: not artwork, but arts work. What is an artist supposed to do?

Some pieces take on the dangers of day-after-tomorrow DNA testing and engineering technology. Heather Dewey-Hagborg is best known for Probably Chelsea, a piece in which she collected DNA samples from Chelsea Manning and generated thirty-two possible portraits of the soldier and activist.

When we worry about biotechnology, we usually worry that our food is going to be dangerous. But sometimes you wish for something thats rare: What happens when biotechnology makes it available to you?

The Gregg is showing a similar piece in which Dewey-Hagborg harvested DNA from cigarette butts and gum she found on the street and created probablebut not definitereplicas of the litterers faces, which hang on the walls above the specimens. Dewey-Hagborg demonstrates not only the unnerving extent of whats currently possible with DNA testing, but also the limits, which create misidentification risks.

Other pieces probe how biotechnology might reshape life as we know it. In a film and a sculpture representing an ancient Greek rite for women, Charlotte Jarvis raises the possibility of creating female sperm, based on the idea that, because stem cells are undifferentiated, you could theoretically teach womens stem cells to develop into sperm.

Still other pieces pointedly poke holes in the boundary between science and art. Adam Zaretskys Errorarium (entitled "Bipolar Flowers")looks like a cross between an arcade cabinet and a terrarium. It houses a few genetically modified Arabidopsis specimens, which Gould calls the white mice of research plants. When you turn the knobs, it changes the sonic parameters of a synthesizer, notionally testing the effects of the sound on the mutant plants.

It doesnt really do anythingor does it? Zaretskys experiment with no hypothesis is a playful tweak on science with something a little dangerous in the background.

Joe Davis, a bio-art pioneer, touches on something similar in his piece, which consists of documentation of an experiment where mice roll dice to determine if luck can be bred. Renda says that Davis couldnt get permission to run the test (universities are wary of drawing attention for ridiculous-seeming experiments), so he did it as conceptual art at N.C. State, instead.

Its notable that two artists home in on luck, one of many human concepts that genetic engineering, which will allow us to take control of our bodies and environment in untested ways, will transform. In We Make Our Own Luck Here, Ciara Redmond has bred four-leaf clovers (without genetic modification), which ruins themtheyrelucks evidence, not its cause. This whimsical iteration of unconsidered consequences raises a serious question: What else are we not thinking of?

When we worry about biotechnology, we usually worry that our food is going to be dangerous, Gould says. But sometimes you wish for something thats rare: What happens when biotechnology makes it available to you?

The exhibit takes an expansive view of biotechnology. Maria McKinney uses semen-extraction straws to sculpt proteins from double-muscled breeding bulls, underscoring that weve been tampering with life since long before CRISPR. Biotech feels radically new, but its revealed as part of a centuries-long process.

Another part of the exhibit, which closed at the end of October but can still be experienced through virtual reality at the Gregg, was From Teosinte to Tomorrow, Rendas land-art project at the North Carolina Museum of Art. In what was essentially a walk back through agricultural history, a bed of teosinte, which is thought to be the ancestor of modern maize, waited at the center of a corn maze.

That teosinte was in some sense genetically enhanced by subsistence farmers in Mexico since the time of the Aztecs, Gould says. Now were doing it in the laboratory with the same genesso whats the difference? Arts work is to make us think and question.

Contact arts and culture editor Brian Howe at bhowe@indyweek.com

Support independent local journalism.Join the INDY Press Clubto help us keep fearless watchdog reporting and essential arts and culture coverage viable in the Triangle.

See the rest here:
At the Crossroads of Art and Biotech, a Warning: Be Careful What You Wish For. - INDY Week

Posted in Genetic Engineering | Comments Off on At the Crossroads of Art and Biotech, a Warning: Be Careful What You Wish For. – INDY Week

The Top Biotech Trends We’ll Be Watching in 2020 – Singularity Hub

Posted: January 13, 2020 at 8:45 pm

Last year left us with this piece of bombshell news: He Jiankui, the mastermind behind the CRISPR babies scandal, has been sentenced to three years in prison for violating Chinese laws on scientific research and medical management. Two of his colleagues also face prison for genetically engineering human embryos that eventually became the worlds first CRISPRd babies.

The story isnt over: at least one other scientist is eagerly following Hes footsteps in creating gene-edited humans, although he stresses that he wont implant any engineered embryos until receiving regulatory approval.

Biotech stories are rarely this dramatic. But as gene editing tools and assisted reproductive technologies increase in safety and precision, were bound to see ever more mind-bending headlines. Add in a dose of deep learning for drug discovery and synthetic biology, and its fair to say were getting closer to reshaping biology from the ground upboth ourselves and other living creatures around us.

Here are two stories in biotech were keeping our eyes on. Although successes likely wont come to fruition this year (sorry), these futuristic projects may be closer to reality than you think.

The idea of human-animal chimeras immediately triggers ethical aversion, but the dream of engineering replacement human organs in other animals is gaining momentum.

There are two main ways to do this. The slightly less ethically-fraught idea is to grow a fleet of pigs with heavily CRISPRd organs to make them more human-like. It sounds crazy, but scientists have already successfully transplanted pig hearts into baboonsa stand-in for people with heart failurewith some recipients living up to 180 days before they were euthanized. Despite having foreign hearts, the baboons were healthy and acted like their normal buoyant selves post-op.

But for cross-species transplantation, or xenotransplants to work in humans, we need to deal with PERVsa group of nasty pig genes scattered across the porcine genome, remnants of ancient viral infections that can tag along and potentially infect unsuspecting human recipients.

Theres plenty of progress here too: back in 2017 scientists at eGenesis, a startup spun off from Dr. George Churchs lab, used CRISPR to make PERV-free pig cells that eventually became PERV-free piglets after cloning. Then last month, eGenesis reported the birth of Pig3.0, the worlds most CRISPRd animal to further increase organ compatibility. These PERV-free genetic wonders had three pig genes that stimulate immunorejection removed, and nine brand new human genes to make themin theorymore compatible with human physiology. When raised to adulthood, pig3.0 could reproduce and pass on their genetic edits.

Although only a first clinical propotype that needs further validation and refinement, eGenesis is hopeful. According to one (perhaps overzealous) estimate, the first pig-to-human xenotranplant clinical trial could come in just two years.

The more ethically-challenged idea is to grow human organs directly inside other animalsin other words, engineer human-animal hybrid embryos and bring them to term. This approach marries two ethically uncomfortable technologies, germline editing and hybrids, into one solution that has many wondering if these engineered animals may somehow receive a dose of humanness by accident during development. What if, for example, human donor cells end up migrating to the hybrid animals brain?

Nevertheless, this year scientists at the University of Tokyo are planning to grow human tissue in rodent and pig embryos and transplant those hybrids into surrogates for further development. For now, bringing the embryos to term is completely out of the question. But the line between humans and other animals will only be further blurred in 2020, and scientists have begun debating a new label, substantially human, for living organisms that are mainly human in characteristicsbut not completely so.

With over 800 gene therapy trials in the running and several in mature stages, well likely see a leap in new gene medicine approvals and growth in CAR-T spheres. For now, although transformative, the three approved gene therapies have had lackluster market results, spurring some to ponder whether companies may cut down on investment.

The research community, however, is going strong, with a curious bifurcating trend emerging. Let me explain.

Genetic medicine, a grab-bag term for treatments that directly change genes or their expression, is usually an off-the-shelf solution. Cell therapies, such as the blood cancer breakthrough CAR-T, are extremely personalized in that a patients own immune cells are genetically enhanced. But the true power of genetic medicine lies in its potential for hyper-personalization, especially when it comes to rare genetic disorders. In contrast, CAR-Ts broader success may eventually rely on its ability to become one-size-fits-all.

One example of hyper-tailored gene medicine success is the harrowing story of Mila, a six-year-old with Batten disease, a neurodegenerative genetic disorder that is always fatal and was previously untreatable. Thanks to remarkable efforts from multiple teams, however, in just over a year scientists developed a new experimental therapy tailored to her unique genetic mutation. Since receiving the drug, Milas condition improved significantly.

Milas case is a proof-of-concept of the power of N=1 genetic medicine. Its unclear whether other children also carry her particular mutationBatten has more than a dozen different variants, each stemming from different genetic miscodingor if anyone else would ever benefit from the treatment.

For now, monumental costs and other necessary resources make it impossible to pull off similar feats for a broader population. This is a shame, because inherited diseases rarely have a single genetic cause. But costs for genome mapping and DNA synthesis are rapidly declining. Were starting to better understand how mutations lead to varied disorders. And with multiple gene medicines, such as antisense oligonucleotides (ASOs) finally making a comeback after 40 years, its not hard to envision a new era of hyper-personalized genetic treatments, especially for rare diseases.

In contrast, the path forward for CAR-T is to strip its personalization. Both FDA-approved CAR-T therapies require doctors to collect a patients own immune T cells, preserved and shipped to a manufacturer, genetically engineered to boost their cancer-hunting abilities, and infused back into patients. Each cycle is a race against the cancer clock, requiring about three to four weeks to manufacture. Shipping and labor costs further drive up the treatments price tag to hundreds of thousands of dollars per treatment.

These considerable problems have pushed scientists to actively research off-the-shelf CAR-T therapies, which can be made from healthy donor cells in giant batches and cryopreserved. The main stumbling block is immunorejection: engineered cells from donors can cause life-threatening immune problems, or be completely eliminated by the cancer patients immune system and lose efficacy.

The good news? Promising results are coming soon. One idea is to use T cells from umbilical cord blood, which are less likely to generate an immune response. Another is to engineer T cells from induced pluripotent stem cells (iPSC)mature cells returned back to a young, stem-like state. A patients skin cells, for example, could be made into iPSCs that constantly renew themselves, and only pushed to develop into cancer-fighting T cells when needed.

Yet another idea is to use gene editing to delete proteins on T cells that can trigger an immune responsethe first clinical trials with this approach are already underway. With at least nine different off-the-shelf CAR-T in early human trials, well likely see movement in industrialized CAR-T this year.

Theres lots of other stories in biotech we here at Singularity Hub are watching. For example, the use of AI in drug discovery, after years of hype, may finally meet its reckoning. That is, can the technology actually speed up the arduous process of finding new drug targets or the design of new drugs?

Another potentially game-changing story is that of Biogens Alzheimers drug candidate, which reported contradicting results last year but was still submitted to the FDA. If approved, itll be the first drug to slow cognitive decline in a decade. And of course, theres always the potential for another mind-breaking technological leap (or stumble?) thats hard to predict.

In other words: we cant wait to bring you new stories from biotechs cutting edge in 2020.

Image Credit: Image by Konstantin Kolosov from Pixabay

Read the original:
The Top Biotech Trends We'll Be Watching in 2020 - Singularity Hub

Posted in Genetic Engineering | Comments Off on The Top Biotech Trends We’ll Be Watching in 2020 – Singularity Hub

Gene editing could revolutionize the food industry, but it’ll have to fight the PR war GMO foods lost – CBC.ca

Posted: January 13, 2020 at 8:45 pm

In his greenhouse at the Cold SpringHarbor Laboratory in Long Island, N.Y., plant geneticist Zach Lippman is growing cherry tomatoes.

But they don't look like the ones that most people grow in their gardens and greenhouses.

Lippman's tomatoes have shorter stemsand the fruit is more tightly clustered, looking more like grapes.

"With gene editing, we now have the ability to fine-tune at will," he said. "So instead of having black or white, small fruit [or] big fruit, you can have everything in between."

Lippman used CRISPR arevolutionarygene-editing tool that can quickly and precisely edit DNA to tweak three of the plant's genes, and make them suitable for large-scale urban agriculture for the first time.

With CRISPR, researchers can precisely target and cut any kind of genetic material. Don't want your mushrooms to turn brown after a few days? Remove the gene that causes thatand problem solved.

There's a lot of excitement about the introduction of gene-edited products into the Canadian food system over the next few years, but a lot of trepidation as well.

The food industry's last foray into genetic engineering genetically modified organisms (GMOs) in the 1990s was a financial success. But the practice is an ongoing public relations nightmare, as many Canadians remain wary of products critics have labelled "Frankenfoods."

Currently, the only gene-edited product commercially available is a soybean oil being used by a restaurant chain in the American Midwest for cooking and salad dressings. It has a longer shelf life than other cooking oils and produces less saturated fat and no trans fat.

Ian Affleck, vice-president of plant biotechnology at CropLife Canada, a trade association that represents Canadian manufacturers of pesticides and plant-breeding products, estimates the soybean oil might be in Canada in a year or two, followed by some altered fruits and vegetables.

Even then, he said, supplies will likely be limited while farmers and food companies determine if consumers will embrace genetically edited food.

All the major health organizations in the world, including Health Canada, have concluded that eating GMO foods does not pose eithershort or long-term health risks.

According to the World Health Organization, GMO goods currently approved for the market "have passed safety assessments and are not likely to present risks for human health."

But Canadians remain stubbornly unconvinced even though about 90 per cent of the corn, soybeansand canola grown in Canada is genetically modified, as is almost all of the processed food we consume.

A 2018 pollby market research company Statista found only 37 per cent of people surveyed strongly or somewhat strongly agreed that GMOs were safe to eat, while 34 per cent strongly or somewhat strongly disagreed.

Industry representatives now say they spent too much time marketing their GMOproducts to farmersand not enough time communicating the benefitsto consumers.

"We spoke to two per cent of the population, who are those who farm," said Affleck. "And those who opposed the technology spoke to the other 98 per cent of the population."

"We thought it was just another transition in plant breeding," recalled Stuart Smyth, who holds the University of Saskatchewan's industry-funded research chair in agri-food innovation. "Nobody expected the environmental groups to develop into a political opposition."

With gene-edited foods, Smyth believes the industry needs to focus on public education to counteract what he calls the "propaganda" that will be coming from the other side.

Gene-edited foods will differ from GMOs in one important respect.

When foods are genetically modified, foreign genes are often added to an existing genome. If you want a vegetable to grow better in cold weather, you could add a gene from a fish that lives in icy water.That's what earned GMO products the "Frankenfoods" moniker.

With gene-editing tools like CRISPR, genes can be cut out, or "turned off," but nothing new is added to the genome.

Lucy Sharratt, co-ordinator of the Canadian Biotechnology Action Network, isn't convinced there's a significant difference.

"The new techniques of gene editing are clearly techniques of genetic engineering," she said. "They are all invasive methods of changing a genome directly at the molecular level.

"While we can produce organisms with new traits, that doesn't mean we know exactly all of what we've done to that organism. There can be many unintended effects," Sharratt further argued.

Unlike GMOs, which require extensive regulatory approval before going to market, gene-edited foods will likely appear without undergoing a risk assessment by Canadian regulators.

Health Canada doesn't require safety testing for new products if it determines those products aren't introducing "novel traits" into the food system. Since it considers gene editing to be an extension of traditional plant breeding, no stamp of approval will be necessary.

That concerns Jennifer Kuzma, co-director of the Genetic Engineering and Society Center at North Carolina State University, whothinks gene-edited products should be tracked and monitored "for those low-level health effects that some products might be contributing to."

Sharratt is also skeptical that gene editing will produce the benefits its supporters claim, pointing to "a biotech industry that has oversold technology and made all kinds of broad promises for the use of genetic engineering that didn't come to pass." Things like reduced pesticide use and greater drought resistance, for example.

Kuzma agrees that GMO researchers have sometimes been guilty of "perhaps overstating the promise of the technology and understating potential risk."But she believes those involved in developing gene-editing techniques want to avoid repeating the mistakes of the past.

"They have a really sincere desire to be more open and transparent in the ways that they communicate and in the sharing of information," she said. "They do realize that the first generation of genetic engineering did not go so well from a public confidence perspective."

The GMO food industry has fiercely opposed one of the most obvious methods to boost public confidence: mandatory labelling, even as a 2018 survey from Dalhousie University showed an overwhelming majority of Canadians support it.

Sixty-four countries require mandatory labelling for GMO products. Canada is not one of them.

There are no plans to require mandatory labelling of gene-edited foods, either.

Jonathan Latham, executive director of the Bioscience Resource Project, a New York-based non-profit organization that researches genetic engineering, thinks that's a mistake.

"If you want people to make informed decisions and you want them to make that in a democratic fashion, then the more information you give them, the better," he said. "And so to deny people information about the content of their food is to violate a very basic democratic right."

Lathamalso believes that not labelling genetically engineered productsincreases consumer skepticism.

"[Consumers] don't really understand why, if a company wants to produce a product and advertise it and tell everybody how good it is, why they shouldn't also want to label it," he said.

Sharratt would like to see Canada adopt the approach taken by the European Court of Justice, which ruled in 2018 that gene-edited foods must undergo the same testing as GMOs before being allowed on grocery store shelves.

Lippman doesn't believe that will happen. In fact, he thinks the potential of gene-edited foods is so great that the public will demand even greater access to suchproducts.

"People will start to be educated and see that there's nothing harmful about it. It's completely fine. And then the only issue sticking out there will be whether we're over-promising.That'll be it."

Click 'listen' above to hear Ira Basen's documentary, The Splice of Life.

Read more here:
Gene editing could revolutionize the food industry, but it'll have to fight the PR war GMO foods lost - CBC.ca

Posted in Genetic Engineering | Comments Off on Gene editing could revolutionize the food industry, but it’ll have to fight the PR war GMO foods lost – CBC.ca

Page 1,183«..1020..1,1821,1831,1841,185..1,1901,200..»